Skip to main content

Landos Biopharma, Inc.

LABPDelisted May 23, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001785345

Landos Biopharma, Inc. was delisted on May 23, 2024; its insiders filed their last Form 4 on May 23, 2024; 16 institutions reported holding it in 13F filings for Q1 2024, worth $34.9M in total; no superinvestor held it.

Q2 2022 vs. Q1 2022

How the institutions holding Landos Biopharma, Inc. changed between Q1 2022 and Q2 2022.

All holders in Q2 2022All holders in Q1 2022

13F holders of LABP: Q1 2022 compared with Q2 2022
MeasureQ1 2022Of which not filed for Q2 2022Q2 2022Change
Holders45135−9
Shares23.9M80222.5M−1.44M (−6.0%)
Value$35.3M$1.00K$16.4M−$18.9M (−53.6%)

1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (8)

Institutions that held Landos Biopharma, Inc. at the end of Q2 2022 but not at the end of Q1 2022.

Institutions new to LABP in Q2 2022
InstitutionSharesValue% of portfolio
Ergoteles LLC22,900$17.0K0.00%
Citadel Advisors LLC21,119$16.0K0.00%
Jane Street Group, LLC20,957$15.0K0.00%
Susquehanna International Group, LLP12,529$9.00K0.00%
Raymond James & Associates10,350$8.00K0.00%
Stratos Wealth Partners, LTD.10,000$7.00K0.00%
UBS Group AG1,243$1.00K0.00%
Credit Suisse AG3$00.00%

Sold out (17)

Institutions that held Landos Biopharma, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.

Not filed for Q2 2022 yet (1)

Institutions that held Landos Biopharma, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding LABP in Q1 2022 that haven't filed for Q2 2022
InstitutionShares, Q1 2022Value, Q1 2022
Amalgamated Financial Corp.802$1.00K